Drugs that contain Futibatinib

1. Lytgobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(8 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833151 TAIHO ONCOLOGY Pharmaceutical composition including sodium alkyl sulfate
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2027
Orphan Drug Exclusivity(ODE-410) Sep 30, 2029

NCE-1 date: 30 September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma


More Information on Dosage

LYTGOBI family patents

Family Patents